Results 161 to 170 of about 836,047 (311)
The influence of fluoxetine on the blood pressure: a meta-analysis of randomized controlled trials. [PDF]
Huang D, Wei W, Prabahar K, Safargar M.
europepmc +1 more source
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis
ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz +9 more
wiley +1 more source
Vinegar Consumption and Health: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials. [PDF]
Shahmohammadi F +3 more
europepmc +1 more source
Reflections on Randomized Control Trials [PDF]
Deaton, Angus, Cartwright, Nancy
openaire +4 more sources
ABSTRACT Objective This analysis evaluates the effect of successful reperfusion on functional outcomes after MT, stratified by admission National Institutes of Health Stroke Scale (NIHSS) and Alberta Stroke Program Early CT Score (ASPECTS) as surrogates for clinical‐core mismatch, using multicenter registry data.
Felix Schlicht +53 more
wiley +1 more source
Randomized Controlled Trials With Statistically Nonsignificant Results
Cope, Mark B, Allison, David B
core +1 more source
Oral Corticosteroid Therapy in Lumbar Radiculopathy: Evidence From Randomized Controlled Trials. [PDF]
Sharma V +7 more
europepmc +1 more source
Clinical Validation of Plasma p‐217tau in Neurological Diseases
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi +13 more
wiley +1 more source

